These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37230889)

  • 1. A booster regime of liposome-delivered live-attenuated CHIKV vaccine RNA genome protects against chikungunya virus disease in mice.
    Rao S; Abeyratne E; Freitas JR; Yang C; Tharmarajah K; Mostafavi H; Liu X; Zaman M; Mahalingam S; Zaid A; Taylor A
    Vaccine; 2023 Jun; 41(27):3976-3988. PubMed ID: 37230889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal Delivery of the RNA Genome of a Live-Attenuated Chikungunya Virus Vaccine Candidate Provides Local, but Not Systemic Protection After One Dose.
    Abeyratne E; Tharmarajah K; Freitas JR; Mostafavi H; Mahalingam S; Zaid A; Zaman M; Taylor A
    Front Immunol; 2020; 11():304. PubMed ID: 32194557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation of the N-Terminal Region of Chikungunya Virus Capsid Protein: Implications for Vaccine Design.
    Taylor A; Liu X; Zaid A; Goh LY; Hobson-Peters J; Hall RA; Merits A; Mahalingam S
    mBio; 2017 Feb; 8(1):. PubMed ID: 28223458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice.
    Tretyakova I; Hearn J; Wang E; Weaver S; Pushko P
    J Infect Dis; 2014 Jun; 209(12):1882-90. PubMed ID: 24585894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chikungunya Virus Vaccine Candidates with Decreased Mutational Robustness Are Attenuated
    Carrau L; Rezelj VV; Noval MG; Levi LI; Megrian D; Blanc H; Weger-Lucarelli J; Moratorio G; Stapleford KA; Vignuzzi M
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31270226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infectious Chikungunya Virus (CHIKV) with a Complete Capsid Deletion: a New Approach for a CHIKV Vaccine.
    Zhang YN; Deng CL; Li JQ; Li N; Zhang QY; Ye HQ; Yuan ZM; Zhang B
    J Virol; 2019 Aug; 93(15):. PubMed ID: 31092567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.
    García-Arriaza J; Cepeda V; Hallengärd D; Sorzano CÓ; Kümmerer BM; Liljeström P; Esteban M
    J Virol; 2014 Mar; 88(6):3527-47. PubMed ID: 24403588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice.
    Hallengärd D; Kakoulidou M; Lulla A; Kümmerer BM; Johansson DX; Mutso M; Lulla V; Fazakerley JK; Roques P; Le Grand R; Merits A; Liljeström P
    J Virol; 2014 Mar; 88(5):2858-66. PubMed ID: 24371047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuation and Stability of CHIKV-NoLS, a Live-Attenuated Chikungunya Virus Vaccine Candidate.
    Abeyratne E; Freitas JR; Zaid A; Mahalingam S; Taylor A
    Vaccines (Basel); 2018 Dec; 7(1):. PubMed ID: 30583514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with a chikungunya virus-like particle vaccine exacerbates disease in aged mice.
    Arévalo MT; Huang Y; Jones CA; Ross TM
    PLoS Negl Trop Dis; 2019 Apr; 13(4):e0007316. PubMed ID: 31026260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Live-attenuated CHIKV vaccine with rearranged genome replicates in vitro and induces immune response in mice.
    Tretyakova I; Joh J; Gearon M; Kraenzle J; Goedeker S; Pignataro A; Alejandro B; Lukashevich IS; Chung D; Pushko P
    PLoS Negl Trop Dis; 2024 Apr; 18(4):e0012120. PubMed ID: 38648230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Live-attenuated RNA hybrid vaccine technology provides single-dose protection against Chikungunya virus.
    Voigt EA; Fuerte-Stone J; Granger B; Archer J; Van Hoeven N
    Mol Ther; 2021 Sep; 29(9):2782-2793. PubMed ID: 34058388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine-Induced Skewing of T Cell Responses Protects Against Chikungunya Virus Disease.
    Broeckel RM; Haese N; Ando T; Dmitriev I; Kreklywich CN; Powers J; Denton M; Smith P; Morrison TE; Heise M; DeFilippis V; Messaoudi I; Curiel DT; Streblow DN
    Front Immunol; 2019; 10():2563. PubMed ID: 31736977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose.
    Roy CJ; Adams AP; Wang E; Plante K; Gorchakov R; Seymour RL; Vinet-Oliphant H; Weaver SC
    J Infect Dis; 2014 Jun; 209(12):1891-9. PubMed ID: 24403555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a next-generation chikungunya virus vaccine based on the HydroVax platform.
    Slifka DK; Raué HP; Weber WC; Andoh TF; Kreklywich CN; DeFilippis VR; Streblow DN; Slifka MK; Amanna IJ
    PLoS Pathog; 2022 Jul; 18(7):e1010695. PubMed ID: 35788221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-Titer Self-Propagating Capsidless Chikungunya Virus Generated in Vero Cells as a Strategy for Alphavirus Vaccine Development.
    Zhang YN; Zhang ZR; Li N; Pei XR; Li XD; Deng CL; Ye HQ; Zhang B
    J Virol; 2022 Mar; 96(6):e0148021. PubMed ID: 35107379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A chikungunya fever vaccine utilizing an insect-specific virus platform.
    Erasmus JH; Auguste AJ; Kaelber JT; Luo H; Rossi SL; Fenton K; Leal G; Kim DY; Chiu W; Wang T; Frolov I; Nasar F; Weaver SC
    Nat Med; 2017 Feb; 23(2):192-199. PubMed ID: 27991917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model.
    Chu H; Das SC; Fuchs JF; Suresh M; Weaver SC; Stinchcomb DT; Partidos CD; Osorio JE
    Vaccine; 2013 Jul; 31(33):3353-60. PubMed ID: 23727003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus.
    Brandler S; Ruffié C; Combredet C; Brault JB; Najburg V; Prevost MC; Habel A; Tauber E; Desprès P; Tangy F
    Vaccine; 2013 Aug; 31(36):3718-25. PubMed ID: 23742993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chikungunya Virus Exposure Partially Cross-Protects against Mayaro Virus Infection in Mice.
    Fumagalli MJ; de Souza WM; de Castro-Jorge LA; de Carvalho RVH; Castro ÍA; de Almeida LGN; Consonni SR; Zamboni DS; Figueiredo LTM
    J Virol; 2021 Nov; 95(23):e0112221. PubMed ID: 34549980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.